Kiniksa Pharmaceuticals International, plc (KNSA) Form 8-K — Oct 27, 2026
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up ~58% year-over-year from $180.9 million, with net income of $47.3 million versus $18.4 million a year ago. The company raised 2026 ARCALYST revenue guidance to $1.045-$1.050 billion from $980-$995 million, positioning the drug for blockbuster status this year. Kiniksa holds $568.8 million in cash and short-term investments with no debt and expects to remain cash flow positive.
Key figures
- Eps
- 0.56
- Revenue
- 286000000
- Guidance
- 2026 ARCALYST net product revenue of $1.045-$1.050 billion (raised from $980-$995 million); 2026 R&D $160-170M; SG&A $270-280M; cash flow positive on an annual basis
- Net Income
- 47300000
- Revenue Yoy
- 58%
- Total Assets
- 983243000
- Cash Position
- 568800000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.